DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix

PARSIPPANY, N.J., Nov. 5 /PRNewswire/ -- DSM Pharmaceutical Products today
announced that it has made a manufacturing alliance with Galenix, Saint Jean
D'Illac, France, where DSM will be the preferred commercial scale
manufacturing partner for Galenix commercial products on a global basis.

DSM and Galenix will collaborate on business development opportunities
co-marketing Galenix drug delivery technologies, based on the strength of
Galenix in drug product development and clinical services and DSM in process
development, scale up and commercial scale pharmaceutical manufacturing.

Pieter de Geus, Senior Vice President, R&D stated, "These innovative drug
delivery technologies enhance our offering in the field of pharmaceutical
development services and complement our portfolio of drug delivery
technologies. The collaboration with Galenix clearly demonstrates DSM's
commitment to bringing improved drug delivery to markets globally."

Hans Engels, President of DSM Pharmaceuticals, Inc. commented, "The alliance
brings out the best of both parties. Combining innovative formulations with
flawless transition into commercial products creates an attractive value
proposition for any drug company."

Jerome Besse, CEO of Galenix concurred with the DSM comments, and further
added, "This is truly a win-win situation. Galenix is privileged in working
with DSM to generate value for our customers. The partnership fits with our
strategic intention of expanding service offerings to the North America
market, and also with DSM's expansion of sales & marketing focus in Europe."

No financial terms were disclosed.

Galenix
Founded in 1993 by CEO Jerome Besse, Galenix is ranked in the top European
leaders for pharmaceutical R&D and drug delivery systems. Galenix provides
comprehensive pharmaceutical development services to healthcare companies,
from the sourcing of Active Pharmaceutical Ingredients (API's) to clinical
supply services and regulatory submission. Its two major competitive
strengths, in addition to a full service delivery, are the compliance of the
cGMP facilities with European and American standards, as well as its extensive
know-how and experience in patented, innovative drug delivery system design
and drug product development. The Galenix drug delivery systems, providing
improvement and better patient compliance of medicines, include Minextab® and
Minextab® floating high-dosage tablet technologies; Microgix® bioavailability
/ solubility technology; Mucolys® film trans-mucosal absorption and Mucolys®
flash sub-lingual absorption technologies; and the ODTx orodispersible
/dispersible oral dosage technology with no need of water to ingest. More
information: www.galenix.fr

DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom
contract manufacturing and development services to the pharmaceutical and
biopharmaceutical industries. DSM contract manufacturing services include:
chemical development, registered intermediates, registered starting materials,
active pharmaceutical ingredients (API's), fermentation, mammalian cell
production of monoclonal antibodies and proteins, formulation development,
clinical trial manufacturing and finished dose form manufacturing of solids,
semi-solids, and scheduled drugs, aseptic liquid and lyophilized products.
More information: www.dsmpharmaceuticals.com

DSM - the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life Sciences and
Materials Sciences that contribute to the quality of life. DSM's products and
services are used globally in a wide range of markets and applications,
supporting a healthier, more sustainable and more enjoyable way of life. End
markets include human and animal nutrition and health, personal care,
pharmaceuticals, automotive, coatings and paint, electrical and electronics,
life protection and housing. DSM has annual net sales of EUR 9.3 billion and
employs some 23,500 people worldwide. The company is headquartered in the
Netherlands, with locations on five continents. DSM is listed on Euronext
Amsterdam. More information: www.dsm.com
For more information:

DSM Pharmaceutical Products
Guy Tiene
Director Marketing and Communications
Tel: 973-257-8160
Email: guy.tiene@dsm.com

Forward-looking statements
This press release may contain forward-looking statements with respect to
DSM's future (financial) performance and position. Such statements are based
on current expectations, estimates and projections of DSM and information
currently available to the company. DSM cautions readers that such statements
involve certain risks and uncertainties that are difficult to predict and
therefore it should be understood that many factors can cause actual
performance and position to differ materially from these statements. DSM has
no obligation to update the statements contained in this press release, unless
required by law.

SOURCE DSM Pharmaceutical Products

DSM Pharmaceutical Products, Guy Tiene, Director Marketing and Communications,
+1-973-257-8160, guy.tiene@dsm.com